Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia: a Randomised Controlled Trial - The NOVEL Trial

NCT03979014 is registered in ClinicalTrials.gov with Imperial College London as lead sponsor.

NCT NCT03979014
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03979014 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Nonavalent Prophylactic HPV Vaccine (GARDASIL9) After Local Conservative Treatment for Cervical Intra-epithelial Neoplasia: a Randomised Controlled Trial - The NOVEL Trial
Lead sponsor
Imperial College London
Phase
Phase 3
Overall status
Completed
Start date
November 1, 2019
Completion date
September 5, 2025
Enrollment
1,099 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasia